This live web event has ended. Thank you for attending.
0 of 12 Sessions Available
-
FEB27
-
APR28
-
SEP03
-
SEP08
-
SEP17
-
DEC02
-
DEC03
-
DEC04
-
DEC09
-
JAN27
-
FEB10
-
FEB19
Contributors
-
Praveen Akuthota, MD
Associate Professor of Medicine
University of California-San Diego
San Diego, CA
Praveen Akuthota, MD is an Associate Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of California-San Diego. Dr. Akuthota’s research efforts range from basic scientific investigations of human eosinophil biology and eosinophilic inflammation to clinical and translational efforts in asthma and eosinophilic pulmonary disease. He is the corresponding Principal Investigator for the UCSD Clinical Center in the National Heart, Lung, and Blood Institute’s PrecISE Network that will be studying precision interventions in severe asthma. He is a co-investigator on a study published in the New England Journal of Medicine showing the efficacy of anti-IL-5 therapy in the treatment of the eosinophilic disease EGPA (Churg-Strauss syndrome). His research group is involved in other multicenter studies in eosinophilic disease and asthma.
Basic science investigations from Dr. Akuthota focus on ex vivo studies of human eosinophils and include published work studying eosinophil trafficking and studying microparticle release by eosinophils. He has written several reviews and chapters discussing eosinophil immunobiology and clinical considerations in eosinophilic diseases. Dr. Akuthota is an At-Large Member of the Board of Directors of the International Eosinophil Society (www.eosinophil-society.org).
-
Michael Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, CO
Michael Wechsler, MD is Director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at NJH in Denver, CO. His research focuses on clinical and translational asthma with an emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome [CSS]). He has led several studies focusing on novel biologic agents for asthma and related diseases, and has published more than 180 peer-reviewed manuscripts relating to asthma, CSS and eosinophilic lung diseases.
Dr. Wechsler was a member of the Steering Committee and site Principal Investigator (PI) for the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multi-center asthma clinical-trials consortium. He serves as the PI of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation, Dr. Wechsler has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society, and the International Eosinophil Society. He is currently Associate Editor of the journal Chest and has served as Associate Editor of Allergy and on the editorial board of the European Journal of Clinical Investigation.
Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and his medical doctorate from McGill University in Montreal. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.